ProQR Therapeutics (NASDAQ:PRQR) Receives Average Recommendation of "Buy" from Analysts

Shares of ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) have been assigned a consensus recommendation of "Buy" from the eight brokerages that are presently covering the company, Marketbeat reports. Seven investment analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $8.75.

Several brokerages have issued reports on PRQR. Citigroup raised ProQR Therapeutics from a "neutral" rating to a "buy" rating and set a $4.00 price objective on the stock in a report on Monday, March 10th. Cantor Fitzgerald began coverage on ProQR Therapeutics in a research report on Tuesday, April 29th. They set an "overweight" rating and a $8.00 price target on the stock. Evercore ISI initiated coverage on shares of ProQR Therapeutics in a research note on Tuesday, April 29th. They set an "outperform" rating and a $5.00 target price for the company. Chardan Capital reissued a "buy" rating and issued a $4.00 target price on shares of ProQR Therapeutics in a report on Friday, March 14th. Finally, HC Wainwright increased their price target on ProQR Therapeutics from $10.00 to $12.00 and gave the stock a "buy" rating in a report on Friday, March 14th.

Institutional Investors Weigh In On ProQR Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Adage Capital Partners GP L.L.C. lifted its holdings in shares of ProQR Therapeutics by 164.9% in the fourth quarter. Adage Capital Partners GP L.L.C. now owns 9,602,280 shares of the biopharmaceutical company's stock valued at $25,446,000 after purchasing an additional 5,976,813 shares in the last quarter. Woodline Partners LP purchased a new stake in ProQR Therapeutics in the 4th quarter valued at approximately $9,426,000. Millennium Management LLC lifted its stake in ProQR Therapeutics by 1,864.4% in the 4th quarter. Millennium Management LLC now owns 2,827,280 shares of the biopharmaceutical company's stock valued at $7,492,000 after buying an additional 2,683,351 shares in the last quarter. Affinity Asset Advisors LLC acquired a new stake in ProQR Therapeutics during the 4th quarter valued at $7,486,000. Finally, DAFNA Capital Management LLC increased its position in ProQR Therapeutics by 73.1% during the fourth quarter. DAFNA Capital Management LLC now owns 1,567,561 shares of the biopharmaceutical company's stock worth $4,154,000 after buying an additional 661,979 shares in the last quarter. 32.65% of the stock is currently owned by hedge funds and other institutional investors.

ProQR Therapeutics Trading Up 3.9 %

Shares of NASDAQ:PRQR opened at $1.61 on Friday. The business has a 50-day moving average price of $1.49 and a 200 day moving average price of $2.40. ProQR Therapeutics has a 12-month low of $1.07 and a 12-month high of $4.62. The company has a market capitalization of $169.39 million, a price-to-earnings ratio of -5.03 and a beta of 0.35.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.02). The firm had revenue of $4.89 million for the quarter, compared to analyst estimates of $4.90 million. ProQR Therapeutics had a negative return on equity of 71.58% and a negative net margin of 134.31%. As a group, equities research analysts predict that ProQR Therapeutics will post -0.31 earnings per share for the current fiscal year.

ProQR Therapeutics Company Profile

ProQR Therapeutics N.V., a biotechnology company, focuses on the discovery and development of novel therapeutic medicines. The company's products pipeline includes AX-0810 for cholestatic diseases targeting Na-taurocholate cotransporting polypeptide (NTCP); and AX-1412 for cardiovascular diseases (CVDs) targeting Beta-1,4-galactosyltransferase 1 (B4GALT1).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.